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Arterial and hepatic uenous blood lcpcls of glucose were 
studied in 12 dogs during orthotopic liver tmllsplantation 
performed under ketamine anesthesw without exogenous 
glucose administration. During the early part of surgery, 
arterial blood glucose levels were stable: 161 ::':: 12 mg/dl 
(mean::':: SEM) after laparotomy and 183 ± 1611lgld15 min 
before tile anhepatic stage. During the anhepatic stage, ar-
terial blood glucose levels decreased progressil.'ely to 135 ::':: 
9 and 88 ± 8 mg/dl, 5 mill ill the anhepatic stage and 5 
min before reperfusion of the graft lil'l'T, respectively (P < 
0.05). Reperfusion of the graft liver resulted in an increase 
in arterial glucose levels to 206 ± 17 and 240 ± 24 IIlg/dl, 
5 and 30 min after repcrfusion, respectively (P < 0.05). 
Significant improvements have been made recently 
in the surgical and anesthetic management of patients 
undergoing liver transplantation (1,2). However, un-
derstanding of glucose metabolism during liver trans-
plantation is still incomplete. Aldrete et al. saw hy-
poglycemia frequently, especially during the anhepatic 
stage of the procedure, and advised that large amounts 
of exogenous glucose be administered during ortho-
topic liver transplantation in humans (3). They as-
cribed the low levels of glucose to the absence of the 
liver, the main producer of blood glucose. Others have 
reported that hypoglycemia did not occur when small 
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Hepatic PCIIOIiS /JIood glucosc 1t?1.'I'ls increased after reper-
fusion (405 ::':: 37 and 346 ::':: 41 mg/dl, 5 and 30 mill after 
reperfusioll, respectiL'ely) and Wt'TC significantly higher than 
in arterial blood (P < 0.05). Arterial plasma inslilin, mea-
sured ill five llnilllals, did not change sigllificantly during 
the procedure, whereas plasma glucagon levels, sta/JIc dur-
ing the preanhepatic and anhepatic stages, increased steadily 
after reperfusion of the graft lit,,:r, from 66.1 ± 14.2 to 
108.4 ::':: 38.1 pglml (P < 0.05). This study shows that in 
dogs with ketllllline allestizesw mild hypoglycemia (xCllrs 
during the anhepatic stage of Ihn transplantation without 
exogenous glucose administration followed by hypergly-
cemia all reperfl/siol! of the graft liper, possibly secondary 
to the release of glucose from the donor liver. 
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amounts of exogenous glucose were administered (4,5). 
Tullock et aJ. reported that without administration of 
exogenous glucose other than tha t in transfused blood, 
blood glucose levels remained within an acceptable 
range during the preanhepatic and anhepatic stages, 
but that hyperglycemia of more than 200 mgldl oc-
curred after reperfusion of the graft liver (4). 
These differences in clinical experience remain 
unexplained; glucose metabolism may have been dif-
ferent among individual recipients, and intraopera-
tive management also may have been different. To 
investigate intraopera~ive glucose metabolism, we 
measured blood levels of glucose, insulin, and glu-
cagon in healthy dogs undergoing liver transplanta-
tion without exogenous glucose infusion. 
Methods 
Orthotopic liver transplantation was performed in 12 
adult beagle dogs, weighing between 11.0 and 14.0 
kg (mean 11.9 kg). The animals fasted overnight. 
Anesthesia was induced and maintained with intra-
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T,]ble I. Laboratory Data during Liver Transplantation in 12 Dogs 
~=~--------~------~--------~------------~-----------------------------------------
Preanhepatic stage Anhepatic stage P05tanhepatic stage 
I + 30 min II - 5 min II + 5 min III - :; min III + ) min III ... 30 min 
;.;:1\. temperature (,C) 
.-\rl,:nal blood 
36.0 :': 0.3 35.1 :': 0.2" 34.2 :': 0.3" 33.7 :: 0.3" 32.9 :: OA'" 32.S :: 0.4" /. 
Hem,] toerit (':( ) 
pH 
1\1Ll), (mm Hg) 
PJl), (mm Hg) 
Base deficit 
-14.3 :': 1.6 
7.43 :': 0.02 
29.3 :': 1.5 
42.4 :': 1.8 
7.43 :': 0.02 
27.3 :': l.2 
34.2 :': 2.3" 
7.42 :': 0.02 
25.0 :+: 1.5" 
34.1 :: 1.7" 
7.34 :: 0.02" 
2b.4 :: 1.8" 
28.5 = 2.3'1,/' 
7.30 :: 0.02'" 
24.b :: 1.5'''' 
21.3 :: 1.9-'/' 
1.23 :: 0.02" /' 
2b.) :: 2.C}' 
154.9 :: 9.5'''' 
:\a (meq/l) 
K (meq/l) 
141.1 :': 11.5 
3.7 :': 0.7 
146.7 :': 0.8 
2.53 :': 0.08 
147.7 :': 12.1 
4.3 :': 0.6 
146.3 :+: 1.1 
2.60 :+: 0.12 
14S.4 :: 7.0 
b.3 :': O.b·' 
142.1 :+: 0.8'''' 
2.S1 :': O.W' 
148.8 :: b.7 
9.7 :': 0.8" 
144.4 ::. 1.4" 
2.78 ::. O.OS" 
154.7 :: 7.6"" 
12.8 :: 0.8"'/' 
HI. 6 :: 1.3",/, 
4.10 :: 0.27"/' 
14.8 :': 0.8"/' 
142.2 :': 1.3" 
3.30 :': 0.20'" 
Hepatic venous blood 
pH 
pvco, (mm Hg) 
PVl)' (mOl Hg) 
Base deficit 
'\Ia (meqIL) 
K (megIL) 
7.42 :+: 0.02 
32.2 :': 1.4' 
57.8 :': 6.3' 
3.3 :': 0.6 
147.0 :': 0,9 
2.63 :': 0.14 
Values are mean = SEM. 
''DiUeren! from the values at I + 30 min. 
'D,Uerent from the values at III - 5 min. 
7.40 :': 0.02 
32.5 :': 1.8' 
43.8 :+: 2.0'" 
3.8 :': 0.5 
145.5 :': 1.1" 
2.87 :': 0.23' 
Diiierent from the corn'sponding values in arterial blood. 
venous ketamine (2 mg/kg followed by 1 mglkg every 
20-30 min), plus pancuronium bromide for muscle 
relaxa tion. The dogs were mechanically ventilated with 
Flo, of 0.3 and end-tidal C02 was maintained between 
-l and 5%. Femoral arterial and jugular venous cath-
eters were inserted for blood sampling and monitor-
ing of arterial and central venous pressures. Crystal-
loid solution without glucose (Plasma-Lyte A, Travenol 
Laboratories, Inc., Deerfield, IL) was infused at a 
rate of 40 ml.kg - I.hr- I. Dopamine was infused to 
maintain mean arterial pressure above 70 torr. The 
surgical technique has been reported elsewhere (6). 
Surgery in the donor and recipient was synchronized 
to minimize donor organ ischemic time. The opera-
tion has three stages: a preanhepatic stage (stage I), 
from the induction of anesthesia to hepatectomy; an 
anhepatic stage (stage II), from hepatectomy to re-
perfusion of the graft; and a postanhepatic stage (stage 
III), from reperfusion of the graft liver to the end of 
surgery. The donor organs were preserved with cold 
(0-4°C) lactated Ringer's solution. In all recipient dogs, 
venous bypass (Bio-Medicus, Inc., Minnetonka, MN) 
\vas used during the anhepatic stage of surgery to 
divert blood from the splenic and femoral veins to the 
jugular vein. The graft liver was reperfused by un-
clamping the portal vein and the supra- and infra-
hepatic inferior vena cava after the vascular anasto-
moses were completed. Throughout the procedure, 
no glucose was administered to the recipient dogs: 
Neither the administered electrolyte solution nor the 
7.15 :: 0.03'" 
44.2 :: 2.8'" 
21.4 :: 2.2"" 
12.4 :: 1.1" 
140.9 :: 1.1" 
4.92 :: 0.50" 
7.14 ::. 0.04'" 
-14.5 :': 3.8'" 
26.0 :': 3.2"" 
12.8 :': 1.3'" 
143.2 :': 1.2" 
3.60 :': 0.26'" 
organ preservation solution contained glucose, and 
no blood was transfused during the study. 
In the preanhepatic stage, femoral arterial and he-
patic venous blood samples were drawn 30 min after 
laparotomy (I + 30 min) and 5 min before the begin-
ning of the anhepatic stage (II - 5 min). Hepatic 
venous blood samples were taken by venipunctures 
at the proximal part of the hepatic vein to avoid con-
tamination by blood from the inferior vena cava. Dur-
ing the anheptic stage, arterial blood was sampled 5 
min after onset (II + 5 min) and 5 min before reper-
fusion of the graft liver (III - 5 min). In the postan-
hepatic stage, arterial and hepatic venous blood sam-
ples were collected 5 min (III + 5 min) and 30 min 
(III + 30 min) after reperfusion of the graft liver. The 
blood samples were analyzed to determine glucose 
levels, arterial blood-gas tensions and acid-base state, 
hematocrit, and levels of Na and K. Blood glucose 
levels were determined using the glucose oxidase test 
(YSI model 23 A glucose analyzer, Yellow Springs 
Instruments Co., Yellow Springs, OH). Arterial in-
sulin and glucagon levels were measured in five an-
imals during the preanhepatic and postanhepatic 
stages using radioimmunoassay technique (Serono 
Diagnostics, Braintree, MA). Data are reported as 
mean ± SEM. Data were analyzed by analysis of 
variance for repeated measures (ANOV A), and spe-
dfic differences were assessed with the Student-
Newman-Keuls test; P < 0.05 was considered 
statistically significant. 
) 
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Figure 1. Blood glucose levels in arterial and hepatic venous blood 
during liver transplantation in 12 dogs. (Values are mean:!: SEM.) 
(.)Different from the values in the preanhepatic stage. (+ )Different 
from the corresponding values in arterial blood. 
Results 
The preanhepatic stage lasted 78 ± 19 min, the an-
hepatic stage 47.5 ± 17 min, and the postanhepatic 
stage 92 ± 24 min. Intraoperatively, cardiovascular 
function was relatively stable except during the sec-
ond half of the anhepatic stage and the first 15 min 
after reperfusion. Dopamine was infused in all ani-
mals to maintain mean arterial pressure above 70 mm 
Hg during the unstable period, the dose ranging from 
5 to 20 ILg.kg -l.min -1. Laboratory data are shown 
in Table 1. All variables were within the normal range 
and stable in the preanhepatic stage. During the an-
hepatic stage, body temperature, hematocrit, and pH 
decreased. Reperfusion of the grafted liver caused a 
further decrease in body temperature, hematocrit, and 
pH. Similar changes occurred in hepatic venous blood 
after reperfusion, although hepatic venous blood was 
significantly more acidotic and had a higher potas-
sium concentration than arterial blood. 
Intraoperative blood glucose levels are presented 
in Figure 1. During the preanhepatic stage (stage I), 
arterial glucose levels were 161 ± 12 and 183 ± 16 
mgidl, and hepatic venous glucose levels were 170 ± 
12 and 202 ± 15 mg/dJ. The latter were slightly higher, 
but not significantly so. During the anhepatic stage 
(stage II), mean blood glucose levels decreased pro-
gressively to 135 ± 9 mg/dl after initiation of the an-
hepatic stage (P < 0.05), and to 88 ± 8 mg/dl im-
mediately before reperfusion of the graft liver (P < 
0.05). Blood glucose levels were between 60 and 70 
mg/dl in three animals and 70 and 80 mg/dl in four 
animals at the end of the anhepatic stage. Blood glu-
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Figure 2. Arterial blood levels of glucagon and insulin during liver 
transplantation in five dogs. (Values are mean:!: SEM.) (.)Different 
from the values in the preanhepatic and anhepatic stages. 
cose levels, increased with reperfusion of the graft 
liver (stage III), were significantly higher in hepatic 
venous blood than in arterial blood: 206 ± 17 mg/dl 
at III + 5 min and 240 ± 24 mg/dl at III + 30 min in 
arterial blood, and 405 ± 37 mg/dl at III + 5 min and 
346 ± 41 mg/dl at III + 30 min in hepatic venous 
blood. Plasma insulin levels, initially 24.3 ± 1.0 
ILIU/ml, did not change significantly during the entire 
observation period (Fig. 2). Plasma glucagon levels 
did not change during the preanhepatic or anhepatic 
stage (71.3 ± 20.5 and 73.9 ± 27.4 pglml, respec-
tively) but increased steadily after reperfusion of the 
graft liver, reaching peak 30 min after reperfusion 
(123.5 ± 33.6 pg/ml), significantly above preanhepatic 
and anhepatic levels. In five animals blood glucose 
levels were compared with the glucagon/insulin ra-
tios, but the correlation was very poor (r2 = 0.02). 
On completion of the study, all dogs were transfused 
with whole blood obtained from the organ donor dogs; 
ten animals received 2 units and two animals received 
3 units. Two animals died of pulmonary edema and 
pneumothorax at the end of surgery. Three animals 
died postoperatively within 48 hr and seven animals 
lived more than 6 postoperative days. 
Discussion 
The liver is responsible for uptake, storage, and re-
lease of glucose, and for gluconeogenesis. The blood 
level of glucose is determined by the balance between 
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release of glucose into the blood stream and glucose 
utilization by the body. These are influenced by, among 
other factors, the activities of insulin, glucagon, cate-
cholamines, and glucocorticoids. Hepatic uptake of 
glucose and glycogen synthesis are enhanced by in-
sulin. Glucagon stimulates gluconeogenesis and gly-
cogenolysis and thereby increases hepatic output of 
glucose. Secretion of glucagon, epinephrine, and 
growth hormone can increase in response to hypo-
glycemia and stress. The liver is exposed to high con-
centrations of insulin and other hormones in portal 
blood, and the effects of these hormones on hepatic 
glucose metabolism may be more important than has 
been recognized. Because of the major role of the liver 
in glucose homeostasis, significant changes in blood 
glucose levels are expected during liver transplanta-
tion in experimental animals and in patients. 
In the animals studied, exogenous glucose admin-
istration, including that in blood transfusions, was 
completely avoided. The dogs had normal preoper-
ative hematocrits, and blood loss during surgery was 
minimal until the postanhepatic stage, so transfusion 
could be delayed until the study was completed (30 
min after reperfusion). In the preanhepatic stage, glu-
cose levels were stable, and arterial and hepatic ve-
nous blood glucose levels were similar, but initiation 
of venous bypass decreased hematocrit and blood glu-
cose levels significantly. These decreases were most 
likely due to hemodilution from the priming solution 
in the bypass system, 250 ml balanced electrolyte so-
lution. As the anhepatic stage progressed, blood glu-
cose levels decreased further, possibly owing to con-
tinuing glucose utilization with decreased glucose 
production. In the present study the mean duration 
of the anhepatic stage was 47.5 min, about one-half 
the 93 min reported in clinical cases (7). With a longer 
anhepatic stage, glucose levels may decrease further 
in animals. Plasma insulin and glucagon levels did 
not change during the preanhepatic .and anhepatic 
stages. Although blood glucose levels decreased dur-
ing the anhepatic stage, the levels may not have been 
low enough to cause glucagon release. 
The changes in metabolic variables with reperfu-
sion are similar to results obtained during human liver 
transplantation: metabolic acidosis, hyperkalemia, 
hemodilution, and hypothermia caused by the release 
of cold, hyperkalemic, acidotic fluid from the graft 
liver (8-10). Reperfusion of the liver significantly in-
creased arterial blood glucose levels. The increase may 
have been secondary to a massive release of glucose 
from the newly implanted liver, as indicated by the 
higher glucose level in hepatic venous blood com-
pared with that in arterial blood and by the association 
A!\:ESTH ANALG 
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of the increasing arterial glucose level with the de-
creasing hepatic venous glucose level. A similar ob-
servation has been made by Halliday et aI., who dem-
onstrated progressively increasing glucose levels in 
the hepatic venous blood of the continuously per-
fused pig donor liver (11). Ischemic injury in the he-
patocytes may have damaged cell membrane perme-
ability, which allowed the release of intracellular glucose 
(12). It is interesting to note that plasma glucagon 
levels progressively increased after reperfusion de-
spite arterial hyperglycemia. The increase in glucagon 
levels may have been caused by delayed release of 
glucagon in response to a low blood sugar level during 
the anhepatic stage or, alternatively, the release of 
glucagon may have played a role in the postreper-
fusion arterial hyperglycemia. However, a positive 
relationship between blood glucose levels and glu-
cagon/insulin ratios was not seen in this study, al-
though the lack of correlation could be due to the 
small number of animals studied. The administration 
of dopamine could have increased the secretion of 
glucagon, but only minimally. Thus, sudden hyper-
glycemia, especially in hepatic venous blood, that oc-
curred within 5 min after reperfusion is unlikely to 
be hormonal in origin. Hypothermia in the recipient 
dogs could have decreased glucose utilization, and 
the relative ischemia of the donor liver occurring after 
reperfusion may also have affected the graft liver's 
sensitivity to hormones and intracellular enzymes re-
sponsible for glycogenolysis. This study was limited 
to 30 min after reperfusion; glucose metabolism in the 
postoperative period requires further investigation. It 
is also unknown whether or not the amount of glucose 
released from the reperfused graft liver has any prog-
nostic value with respect to functional recovery of the 
organ, if postreperfusion hyperglycemia were caused 
by ischemic damage of the donor liver. 
Similar changes in glucose homeostasis are ex-
pected to be seen in patients receiving liver trans-
plants, although there are several differences between 
our experimental design and clinical patient care. In 
the animals studied, anesthesia was maintained with 
ketamine, which could have increased blood glucose 
level indirectly by releasing catecholamines (13), and 
the duration of the anhepatic stage was shorter than 
that in patients, which might have led to the higher 
glucose level than the values expected in patients. 
However, hyperglycemia is more likely to occur in 
patients undergoing liver transplantation. Glucose 
metabolism is altered in patients with chronic liver 
disease, and high levels of circulating insulin are com-
mon owing to hypersecretion of insulin or inadequate 
hepatic clearance of insulin (14), but these patients 
.,..,..-.. --.-.... - .. ----------..... - ..•. - .. -.- .. -K--K--~---... _-----
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are known to be resistant to insulin action (15). A 
high plasma glucagon level is frequently observed, 
caused by hypersecretion and the effects of portasys-
temic shunting (16). Clinically. glucose intolerance and 
higher than normal blood glucose levels are not un-
usual. In patients. the intraoperative transfusion of 
blood preserved in dextrose solution (CrDA-l). which 
contains 200 mg/dl of glucose, is unavoidable, and 
flushing of preservation solution (Collins' solution, 
glucose 3.75%) into the systemic circulation may sup-
ply enough glucose to maintain adequate glucose lev-
els. The high catecholamine levels observed in pa-
tients receiving liver transplants (Uram et al., 
unpublished data, 1984) may counteract the periph-
eral effects of insulin, and possible disturbances of 
the hormonal balance between insulin and glucagon 
may occur. Furthermore, the donor organ with a longer 
ischemic time in patients (4-8 hr) (1) may release more 
glucose on reperfusion, whereas, glucose utilization 
is decreased by frequent inadvertent hypothermia. 
The effects of postreperfusion hyperglycemia on urine 
output and its composition were not determined in 
the present study. Hyperglycemia exceeding the 
transport maximum of the renal tubules may cause 
glucosuria and osmotic diuresis. 
In conclusion, this study showed minimal hypo-
glycemia during the anhepatic stage and hypergly-
cemia after reperfusion of the graft liver in healthy 
dogs undergoing liver transplantation. without ex-
ogenous glucose administration. The postreperfusion 
hyperglycemia appears to be secondary to a release 
of glucose from the newly grafted liver. The results 
suggest that hypoglycemia is less likely in patients 
when glucose is administered by transfusion of banked 
blood. and hyperglycemia may occur if additional ex-
ogenous glucose is given, especially after reperfusion 
of the graft liver. 
Thl' authors thank Marc Zapp and Frank McSteen for their technical 
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